A Phase IV Study in Drug-Naive Patients with T2DM in China

Trial Identifier: D1690C00060
Sponsor: AstraZeneca
NCTID:: NCT03344341
Start Date: December 2017
Primary Completion Date: May 2019
Study Completion Date: May 2019
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Simplified Chinese Translation

Trial Locations

Country Location
China Beijing, China, 100020
China Beijing, China, 100034
China Beijing, China, 100730
China Changsha, China, 410013
China Changsha, China, 430033
China Changsha, China, 410008
China Chengdu, China, 610041
China Chongqing, China, 400016
China Guangzhou, China, 510280
China Guiyang, China
China Hangzhou, China, 310016
China Hangzhou, China, 310014
China Hefei, China, 230022
China Jinan, China, 250012
China Kunming, China, 650032
China Nanjing, China, 2100008
China Nanjing, China, 210029
China Qingdao, China, 266003
China Qingdao, China
China Shanghai, China, 200032
China Shanghai, China, CN-200120
China Shanghai, China, 200233
China Shenyang, China, 100003
China Shenyang, China, 110001
China Suzhou, China, 215004
China Tianjin, China, CN-300070
China Urumqi, China, 830054
China Xi'an, China, 710061
China Xining, China, 810001
China Yinchuan, China, 750004